Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
1. The 5-year disease-free survival was 80.3% in the exercise group and 73.9% in the education group, with an overall...
Oncology
Reports of high-impact oncology studies by medical professionals
Breast cancer survivors may have a lower risk of Alzheimer’s dementia
1. In this retrospective cohort study, breast cancer survivors had a lower risk of Alzheimer’s dementia compared with cancer-free controls. ...
Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts
1. Abbreviated MRI detected three times as many invasive cancers compared with ABUS. 2. Contrast-enhanced mammography detected a greater number...
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR...
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR...
Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events...
Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
1. In patients with previously treated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with sacituzumab...
Birth cohort effects observed for increased appendiceal adenocarcinoma incidence
1. In this retrospective cohort study, age-specific incidence rates of appendiceal adenocarcinoma increased by time period. 2. Local drift for...
Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer
1. In this Australian cohort of adults, individuals diagnosed with cancer experienced greater declines in physical functioning and slightly higher...
Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis
1. Among patients with active cancer and prior venous thromboembolism (VTE), extended treatment with reduced-dose apixaban demonstrated noninferior efficacy to...